葛根素联合复方丹参注射液对不稳定型心绞痛患者凝血纤溶活性的影响

The study of effects of combination of puerarin and compound salvia miltiorrhiza on thrombogenic and fibrinolytic activities in patients with unstable angina pectoris

目的探讨葛根素联用复方丹参注射液对不稳定型心绞痛患者凝血纤溶活性的影响及临床疗效。方法随机选择不稳定型心绞痛患者100例,在常规治疗基础上随机分为治疗组50例和对照组50例。对照组静滴复方丹参注射液14d,治疗组静滴葛根素和复方丹参注射液14d,观察两组患者凝血纤溶活性指标以及心绞痛和心电图疗效。结果两组患者治疗后血纤溶酶原激活抑制物-1(PAI-1)、血管性假血友病因子(VWF)和纤维蛋白原水平较治疗前低(均为P<0.05),抗凝血酶Ⅲ(AT-Ⅲ)和组织纤溶酶原激活剂(t-PA)水平较治疗前高,但治疗组改变较对照组更为明显(P<0.05)。治疗组心绞痛和心电图疗效高于对照组(P<0.05)。两组患者不良反应差别无统计学意义(P>0.05)。结论与单用复方丹参注射液相比,葛根素联用复方丹参注射液能更加明显地改善不稳定型心绞痛患者的凝血纤溶状态,临床疗效更好,是治疗不稳定型心绞痛的理想方法。

Objective To study the curative effects and influence of fibrinolytic and thrombogenic activities after puerarin and compound salvia mihiorrhiza therapy on patients with unstable angina pectoris. Methods 100 cases of unstable angina pectoris patients were randomly choose and randomly divided into two groups, which include treatment group （50 cases） and control group （50 cases ） on the basis of traditional therapy. The patients in treatment group were administrated puerarin and compound salvia mihiorrhiza for 14 days and those in control group were only administrated compound salvia mihiorrhiza for 14 days. The parameters of fibrinolytic or thrombogenic activities and therapy effects of angina pectoris,ECG of patients in two groups were observed. Results In both groups, the serum levels of von willebrand factor（VWF）, plasminogen activator inhibitor-1 （PAI-1）and fibrinogen were lower than those before treatment （P〈0.05）, and the serum levels of tissue plasminogen activator（t-PA）and antithrombin Ⅲ （AT- Ⅲ ） were higher than those before treatment （P〈0.05）. Compared with the control group, the changes in treatment group were significant （P〈0.05）. The therapy effects of angina pectoris and ECG of patients in treatment group were higher than those of the control group （P〈0.05）. There was no significant difference between the side effects of two groups（P〈0.05）. Conclusion Compared with compound salvia miltiorrhiza, combination of puerarin and compound salvia miltiorrhiza can effectively improve fibrinolytic and thrombogenic activities in patients with unstable angina pectoris, and presented good clinical therapy effects. It is an ideal regimen for treatment of unstable angina pectoris.